It has been reported that the use of mitochondrial RNA aptamers including RNase P (RP) results in the selective mitochondrial delivery of endogenous and exogenous RNAs. The issue of whether these aptamers would be useful ligands for the mitochondrial targeting of a nanoparticle has not been demonstrated to date, because nanocarriers modified with these RNA aptamers are insufficiently internalized by cells.
Introduction
If it was possible to develop an active targeting system that could target a specific organelle, this would open a new field of research directed toward therapy for various diseases. Mitochondria are promising targets for delivering therapeutic molecules 1 . Mitochondrial dysfunctions are implicated in a variety of human diseases, including neurodegenerative disorders, ischemia reperfusion injury, cancer and inherited mitochondrial diseases [2] [3] [4] [5] . Accordingly, it would be expected that delivering therapeutic molecules to mitochondria in diseased cells be a strategy for the treatment of mitochondrial dysfunctions, resulting in the suppression of mitochondrial related diseases.
The mitochondrial targeting signal peptide (MTS), which is necessary for targeting nuclear-encoded protein to mitochondria, is useful as a specific ligand for mitochondria 6, 7 . Previous reports showed that the conjugation or direct modification of MTS permitted a macromolecule such as a protein, DNA and a liposomal nanocarrier to be delivered to mitochondria [8] [9] [10] [11] [12] . On the other hand, some researchers have reported the use of a mitochondrial RNA aptamer for mitochondrial delivery. The mitochondrial import of mitochondrial ribozyme, RNase P (RP) and mitochondrial RNase P (MRP)
were reported to be mediated by polynucleotide phosphorylase (PNPase) 13 . Wang and coworkers showed that allotropically encoded mitochondrial mRNAs and tRNA were imported by RP and MRP aptamers into mitochondria 13, 14 . Adhya and coworkers reported that the combination of a mitochondrial tRNA import signal (D-arm) and a RNA import complex (RIC), which were found in Leichmania tropica, induced the transport of tRNA and antisense RNA into mitochondria in living cells 15 . However, the direct modification of a mitochondrial RNA aptamer on a nanocarrier has not been a subject of extensive investigation.
The present study focused on enhancing mitochondrial targeting by modification of a liposomal based nanocarrier with a mitochondrial RNA aptamer. The mitochondrial RNA aptamers used in this study included RP and MRP, in which mitochondrial delivery occurs via PNPase 13 , and the D-arm with a high affinity with the tubulin antisense binding protein (TAB) located on the mitochondrial outer membrane 16 ( Table 1) . These RNA aptamers themselves have mitochondrial targeting activity, but modifying the carrier with a single aptamer would not be sufficient to allow the particle to be internalized by a cell. We recently reported on the development of a mitochondrial delivery system, a MITO-Porter in which the surface is modified with octaarginine (R8). The R8 functions as both a cellular uptake device via macropinocytosis and as a mitochondrial targeting peptide via electrostatic interactions with negatively charged mitochondria [17] [18] [19] . We also developed a dual-ligand system in which the nanocarrier is modified with a specific ligand and R8 20, 21 . These systems have a synergistic effect on both selectivity and cellular uptake.
Thus, we expected that a dual-ligand liposomal system modified with both R8
and a mitochondrial RNA aptamer would show an enhanced mitochondrial delivery. In this study, we prepared a dual-ligand modified MITO-Porter composed of R8 with different amounts of mitochondrial RNA aptamers including RP, MRP and the D-arm.
We then evaluated the cellular uptake efficiency of the carriers using flow cytometry.
The extent of intracellular trafficking was observed by confocal laser scanning microscopy (CLSM), and the mitochondrial targeting rate and mitochondrial occupancy rate were estimated based on the obtained CLSM images.
Materials and Methods

Chemicals and materials
and DOPE-N-(7-nitro-2-1,3-benzoxadiazole-4-yl) (NBD-DOPE) were purchased from Avanti Polar lipids (Alabaster, AL). Stearylated R8 (STR-R8) Table 1 . HeLa human cervix carcinoma cells were obtained from the RIKEN Cell Bank (Tsukuba, Japan).
Dulbecco's modified Eagle medium (DMEM) and fetal bovine serum were purchased from Invitrogen (Carlsbad, CA). Amirolide, filipin III, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) and oligomycin were purchased from SIGMA (St Louis, MO). All other chemicals used were commercially available reagent-grade products.
Preparation of dual-ligand modified MITO-Porter
Dual-ligand modified MITO-Porter was constructed by the hydration method 17 .
A lipid film was formed by the evaporation of a chloroform/ethanol solution containing DOPE/SM/NBD-DOPE (9:2:0.1, molar ratio). NBD-DOPE was added to the lipid composition as a tracer for the MITO-Porter. To prepare the dual-ligand modified MITO-Porter, 1-4 mol% of Chol-RNA aptamers were added to the lipid composition.
The 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 7.4) was applied to the lipid film, followed by incubation for 15 min at room temperature to hydrate the lipids. The lipid film was sonicated for approximately 1 min in a bath-type sonicator. An STR-R8 solution (10 mol% total lipid) was added to the suspension to attach the R8 to the surface.
Characterization of prepared carriers
Particle diameters were measured using a dynamic light scattering (DLS) method (Zetasizer Nano ZS; Malvern Instruments, Worcestershire, UK). Samples were prepared in 10 mM HEPES buffer at 25°C and the values of particle diameters are shown in the form of volume distribution. The ζ-potentials of samples were also determined in 10 mM HEPES buffer at 25°C using a Zetasizer Nano ZS.
Cell cultures
HeLa cells were maintained in complete medium, which is DMEM supplemented with 10% FBS, penicillin (100 units/mL), and streptomycin (100 μg/mL).
The cells were cultured under an atmosphere of 5% CO2/air at 37°C. One day before transfection, the HeLa cells were seeded on plates or dishes for each experiment.
Immediately before transfection, the medium was replaced to serum-free medium, DMEM unsupplemented with antibiotics. 
Cellular uptake analysis using flow cytometry
Evaluation of mitochondrial targeting and mitochondrial occupancy based on
CLSM images
Mitochondrial targeting and the mitochondrial occupancy of carriers were evaluated using Image Pro-Plus (Ropper Industries, Sarasota, FL), as described below.
Fluorescent and bright-field cell images, after treatment with NBD labeled carriers (green), followed by staining mitochondria red, were captured by means of CLSM, as shown in Mitochondrial occupancy rate ( Figure 4C ) was calculated as follows;
Mitochondrial occupancy rate (%) = S (yellow) / S (red) × 100 (3) This value indicates the rate that the carriers accumulated with mitochondrial region of total mitochondrial region in cell, and is used to evaluate the accumulation of the carriers in mitochondria.
Statistical Analysis
Each of the values shown in Table 2 Figure 1A and 6, the statistical significances between two groups were examined by the unpaired student's t-test. In Figure 2 , 4B and 4C, we performed one-way ANOVA followed by bonfferoni test for multiple comparisons. In Figure 1B , 5A (e) and 5B (e), we performed two-way ANOVA analysis followed by bonferroni test to compare the effect of two factors. If a significant interaction between the two factors was found, a simple main effect test also performed. Levels of P < 0.05 were considered to be significant.
Results
Construction of dual-ligand modified MITO-Porter
Chol-RNA aptamers, including RP, MRP and the D-arm, were used to prepare the dual-ligand modified MITO-Porter (RP/R8-modified MITO-Porter, MRP/R8-modified MITO-Porter and D-arm/R8-modified MITO-Porter). Information regarding the RNA aptamers used in this study is shown in Table 1 . The physicochemical properties of the prepared carriers are summarized in Table 2 . Their diameters were approximately 100-150 nm. Modification of a negatively charged RNA aptamer on the positively charged R8-modified MITO-Porter reduced the ζ-potentials from a positive charge to a negative charge, and the values became saturated when the modification ratio of RNA-aptamer exceeded 2.5 mol% of the total lipids. These results indicate that it is possible to attach the mitochondrial RNA aptamer to the surface of the R8-modified MITO-Porter.
Effect of the mitochondrial RNA aptamer modification on the cellular uptake of R8-modified MITO-Porter
We investigated the effect of mitochondrial RNA aptamer modification on the cellular uptake of the R8-modified MITO-Porter. Figure 1B . The cellular uptake of the R8-modified MITO-Porter was enhanced by modification with the RNA aptamer, while the single modification of the RNA aptamer on R8-unmodified MITO-Porter had no effect on cellular uptake.
We also performed a two-way ANOVA analysis to compare the two factors that are "aptamer type" and "modification ratio of the R8 / RNA aptamer". As a result, 1 mol% and a 2.5 mol% modification of RNA aptamers on the R8-modified MITO-Porter significantly increased in the cellular uptake values compared with the R8-unmodified MITO-Porter among "modification ratio of R8/aptamer" ( ### P < 0.001). No significant difference in different "aptamer type" on the cellular uptake value (P = 0.21) and no interaction between two factor (P = 0.14) was found, suggesting that the enhancement in the cellular uptake of the R8-modified MITO-Porter by the modification with the RNA aptamer would be independent on "aptamer type". The 2.5 mol% modification with RP on the R8-modified MITO-Porter indicated the highest cellular uptake value among all variants of the MITO-Porter. For the following studies, 2.5 mol% RNA aptamer was modified on the surface of the R8-modified MITO-Porters.
Investigation of the cellular uptake pathway of dual-ligand modified MITO-Porter
To investigate whether the modification with a RNA aptamer affects the cellular uptake pathway of the R8-modified MITO-Porter, cellular uptake was evaluated in the presence of cellular uptake inhibitors (Figure 2) . A hypertonic medium (sucrose) was used to inhibit clathrin-mediated endocytosis via the dissociation of the clathrin lattice 23 . Amiloride inhibits mactopinocytosis by inhibiting the Na targeting rate than that for the R8-modified MITO-Porter ( Figure 4B ). The mitochondrial occupancy rate of each carrier was also calculated. This value indicates that the carriers accumulated within the mitochondrial region of the total mitochondrial region in the cell, and is used to evaluate the mitochondrial accumulation of the carriers.
As shown in Figure 4C , the values for the dual-ligand modified MITO-Porter were higher than that for the R8-modified MITO-Porter with a similar mitochondrial targeting rate. The RP/R8-modified MITO-Porter showed the highest mitochondrial targeting rate ( Figure 4B ) and mitochondrial occupancy ( Figure 4C ) among other dual-ligand modified MITO-Porters. Thus, the RP/R8-modified MITO-Porter was used in the following experiments as an optimal dual-ligand modified MITO-Porter.
Investigation of the mitochondrial targeting manner of dual-ligand modified
MITO-Porter.
To investigate the effect of mitochondrial membrane potential on the mitochondrial targeting of the RP/R8-modified MITO-Porter and the R8-modified MITO-Porters, the intracellular trafficking of the carriers was observed in the presence/absence of FCCP ( Figures 5A, S1 ). FCCP, an uncoupling regent, is a proton ionophore that depolarizes the mitochondrial membrane potential 26 . In the FCCP treatment, only green dots were observed in cells in the case of the RP/R8-modified MITO-Porter ( Figure 5A (d) ) and the R8-modified MITO-Porter ( Figure 5A (c) ).
The relative mitochondrial targeting rates were estimated based on the CLSM image shown in Figure 5A (a-d), and a two-way ANOVA analysis was performed to compare the effect of the two factors, i.e., the "carrier type" and the "FCCP treatment"
( Figure 5A (e)). Significant differences were detected between presence and absence of FCCP (P < 0.001), while there was no significant difference for the different "carrier type" (P = 0.72) and no interaction between two factors (P = 0.72). These analytical results indicate that mitochondrial targeting of both the RP/R8 modified MITO-Porter and the R8-modified MITO-Porter was drastically inhibited when the cells were treated with FCCP.
We also evaluated the effect of ATP depletion on mitochondrial targeting using oligomycin ( Figures 5B, S2 ), an inhibitor of ATP synthase that functions by blocking the proton channel (Fo subunit) for the oxidative phosphorylation of ADP to ATP 27 . In this experiment the RP/R8-modified MITO-Porter was observed as green dots in cells ( Figure 5B (d) ), while the R8-modified MITO-Porter was observed as yellow dots in the oligomycin treatment experiment ( Figure 5B (c) ).
In Figure 5B (e), the relative mitochondrial targeting rates were evaluated and two-way ANOVA analysis was performed. There were significant difference between the different "carrier type" (P < 0.01) and with/without "oligomycin treatment" (P < 0.001), and also a significant interaction between two factors (P < 0.01). The use of a simple main effect test indicated the existence of significant differences between the presence and absence of oligomycin in the case of both carriers (***P < 0.001),
suggesting that ATP depletion affects the mitochondrial targeting of the RP/R8 and the R8 modified MITO-Porter. We also detected a significant difference between the R8-modified MITO-Porter and the RP/R8-modified MITO-Porter with an "oligomycin treatment" (***P < 0.001), suggesting that the mitochondrial targeting of the RP/R8-modified MITO-Porter was significantly decreased by ATP depletion compared with the R8-modified MITO-Porter.
Moreover, we investigated the cellular uptake of the carriers in the presence of 
Discussion
The present study focused on strategies for enhancing mitochondrial targeting by modification of a liposomal based nanocarrier with a mitochondrial RNA aptamer.
To evaluate the targeting of the nanocarrier to mitochondria in living cells, we developed a dual-ligand system, in which the nanocarrier is modified with a mitochondrial RNA aptamer and R8. We expected that R8, which is reported to function as a cellular uptake device for a liposomal carrier [17] [18] [19] , would assist the cellular internalization of the RNA aptamer-modified MITO-Porter with poor cellular uptake activity. The findings indicate, however, that "cellular uptake" and "mitochondrial targeting" between dual ligand-modified MITO-Porter and R8-modified MITO-Porter occur in significantly different manners. This aspect is discussed in detail.
In the cellar uptake analysis shown in Figure 1 , modification of R8-modified MITO-Porter with the RNA aptamer enhanced the cellular uptake. The value of 2.5 mol% RP/R8-modified MITO-Porter (about 56 cellular uptake value) was 2 fold higher than that for the R8-modified MITO-Porter (about a 28 cellular uptake value). On the other hand, a single modification of the carrier with the RNA aptamer had essentially no effect on cellular uptake. The findings also confirmed that the cellular uptake of the dual-ligand modified MITO-Porter proceeded mainly via the R8-mediated pathway including clathrin mediated endocytosis and macropinocytosis, as shown in Figure 2 .
Based on these results, we presumed that the RNA aptamer modification would contribute to an increase in the R8-mediated pathway.
That the RNA aptamer was attached to the surface of the R8-modified MITO-Porter was confirmed based on physicochemical properties such as ζ potentials (Table 2 ). These results indicate that the RNA aptamer coats the entire surface of the R8-modified MITO-Porter, but may not be able to inactivate the R8-mediated pathway.
We previously found a similar phenomenon that modification of the R8-modified carriers with hyaluronic acid resulted in a negatively charged carrier surface, while the cellular uptake activity of R8-modified carriers with or without hyaluronic acid were comparable 28 . As an explanation for this, it is possible that the head group of R8 could be displayed on the RNA aptamer coated carrier-surface, and a part of the R8 could then induce cellular uptake.
In this scenario, R8 might be displayed on the MITO-Porter as a topology favorable to cellular uptake by RNA aptamer modification at the optimal amount (2.5 mol%). While, an excess amount of RNA aptamer (4.0 mol%) might mask even the head group of R8 displayed on the RNA aptamer coated carrier-surface, resulting in a decrease in cellular uptake. We presumed that the ratio of RNA aptamer modified on the R8-modified MITO-Porter might affect the cellular uptake activity of R8, although the ζ-potentials of a 2.5 mol% and 4.0 mol% RNA aptamer-modified carriers were comparable ( Table 2) .
We also observed that a loss of mitochondrial membrane potential resulting from an FCCP treatment largely affected the cellular uptake of the RP/R8-modified MITO-Porter. As shown in Figure 6A , the cellular uptake of the RP/R8-modified MITO-Porter was drastically decreased to about 20 % as the result of the FCCP treatment, while that of the R8-modified MITO-Porter was not affected by the FCCP treatment. Based on these results, we hypothesized that the RP/R8-modified MITO-Porter might use, not only the R8-mediated pathway, but also a yet to be discovered uptake pathway. This unknown uptake pathway might be driven by a certain cell function that is dependent of mitochondrial membrane potential.
The effect of the RNA aptamer on enhancing the cellular uptake of 
Conclusion
The results presented herein constitute the first report of the use of a mitochondrial RNA aptamer modified nanocarrier system to regulate intracellular trafficking, although lipophilic and cationic peptide-based mitochondrial targeting has been reported in previous studies 12, 19, [33] [34] [35] . In this study, we determined the optimal dual-ligand system for a nanocarrier for achieving efficient cellular uptake and mitochondrial targeting (RP/R8-modified MITO-Porter). However, more improvements in selective mitochondrial targeting are needed, since the mitochondrial occupancy rate was only 30%. We previously reported on the use of RNA aptamers for targeting mitochondria using mitochondria-based systematic evolution of ligands by the exponential enrichment (SELEX) method, which are referred to as Mitomers (n=3-4). We performed a two-way ANOVA analysis to compare the effect of multiple levels of two factors that are the "aptamer type" and the "modification ratio of R8/aptamer".
###
Significant differences between R8-unmodified carrier and other carriers among "modification ratio of R8/aptamer" (p < 0.001 by two-way ANOVA, followed by bonferroni test). There was no significant difference of different "aptamer type" on the cellular uptake value and no interaction between two factors. Data are represented as the mean with SEM (n=3). In each carrier, significant differences between non treatment and others were calculated by one-way ANOVA, followed by bonfferoni test (**p<0.01, *p<0.05). Figure 5A ) and oligomycin treatment (a-d in Figure 5B ). Scale bars; 30 μm. Relative mitochondrial targeting rates (e) were evaluated based on CLSM image. Data are represented as the mean with SEM (n=22-36). In Figure 5A (e), we performed two-way ANOVA analysis to compare the effect of two factors that are "carrier type" and "FCCP treatment". In Figure 5B (e), we performed a two-way ANOVA analysis to compare the effect of two factors that are "carrier type" and "oligomycin treatment". Since there was significant interaction between two factors, simple main effect test also performed. *** indicate significant differences (p < 0.001 by simple main effect test, followed by Bonferroni correction). 
